A study to investigate trend of IgE levels in patients receiving biologics for different allergic conditions and if patients become IgE decient in real-clinical settings
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Hypersensitivity
- Focus Pharmacodynamics
- 22 Apr 2021 New trial record
- 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology